Key facts
- Adcendo’s last known valuation is $209.9M (Nov 2024).
- It has raised $315.9M across 2 recorded rounds; the latest was Later Stage VC (Series B) ($134.1M) in Nov 2024.
- Notable investors include Bpifrance, RA Capital Management, OrbiMed, InnoFounder, Novo Holdings — 21 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Adcendo
Funding rounds
2 roundsAbout Adcendo
Developer of antibody-drug conjugates designed to create new medicines for cancer patients with significant unmet needs. The company's conjugates are directed at a target receptor, which is an approach that helps targeted therapy in several cancer forms where expression of the target is unregulated, including soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, enabling doctors to treat patients with diseases such as carcinomas, breast, colon, pancreatic, prostate, ovarian, and renal cancers.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Frederiksberg, Denmark
- Founded
- 2017
- Employees
- 60
- Website
- adcendo.com/
- Ownership
- Privately Held (backing)
Adcendo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adcendo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adcendo in its N-PORT filings yet. We sweep new filings monthly.